Tiazac (diltiazem hydrochloride)

Company: Forest Laboratories
Approval Status: Approved February 1998
Treatment for: chronic stable angina
Areas: Cardiovascular / Cardiology
Possible similar drugs: Tiazac; Tiazac

General Information

Tiazac has been approved for use in the treatment of chronic stable angina. Tiazac was previously approved for the treatment of hypertension.

Clinical Results

Tiazac has been shown to significantly reduce both angina attack rates and nitroglycerin consumption. Tiazac's central effects and peripheral vasodilating action balanced oxygen supply and demand producing significantly greater increases in total duration of exercise compared to placebo. Additionally, Tiazac effectively reduced blood pressure of hypertensive patients over a 24-hour dosing interval.

Side Effects

Side Effects: The side-effect profile is comparable to placebo, even when dosed up to 360 mg.

Mechanism of Action

Tiazac (diltiazem HCl) is a once-daily calcium channel blocker.

< back to top

Tiazac Drug Information

The Tiazac drug information shown above is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.